{"id":71787,"date":"2026-08-06T00:42:34","date_gmt":"2026-08-05T16:42:34","guid":{"rendered":"https:\/\/flcube.com\/?p=71787"},"modified":"2026-08-06T00:42:35","modified_gmt":"2026-08-05T16:42:35","slug":"merck-reports-q2-2026-sales-of-16-6b-driven-by-keytruda-growth-and-winrevair-surge-as-company-raises-full-year-guidance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71787","title":{"rendered":"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Merck &amp; Co., Inc.<\/strong> (MSD; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) reported financial results for the second quarter of 2026, with <strong>total worldwide sales of USD 16.6 billion<\/strong>, growing <strong>4% year-over-year<\/strong> (ex-FX). The company is <strong>raising and narrowing its full-year 2026 sales outlook<\/strong> to a range of <strong>USD 66.3 billion to USD 67.3 billion<\/strong>, reflecting continued strength in oncology and successful recent launches.<\/p>\n\n\n\n<h2 id=\"h-financial-performance-snapshot\" class=\"wp-block-heading\">Financial Performance Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q2 2026<\/th><th>YoY Change (ex-FX)<\/th><th>Full-Year 2026 Guidance<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Worldwide Sales<\/strong><\/td><td>USD 16.6B<\/td><td>+4%<\/td><td>USD 66.3\u201367.3B (raised and narrowed)<\/td><\/tr><tr><td><strong>Keytruda Franchise<\/strong><\/td><td>USD 8.4B<\/td><td>+4%<\/td><td>Core growth driver<\/td><\/tr><tr><td><strong>Keytruda QLEX<\/strong><\/td><td>USD 463M<\/td><td>Not disclosed (new launch)<\/td><td>Subcutaneous formulation gaining traction<\/td><\/tr><tr><td><strong>Winrevair<\/strong><\/td><td>USD 588M<\/td><td>+75%<\/td><td>Pulmonary arterial hypertension blockbuster<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-oncology-portfolio-performance\" class=\"wp-block-heading\">Oncology Portfolio Performance<\/h2>\n\n\n\n<h3 id=\"h-keytruda-franchise-expansion\" class=\"wp-block-heading\">Keytruda Franchise Expansion<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Keytruda Revenue<\/strong>: USD 8.4 billion (+4% YoY)<\/li>\n\n\n\n<li><strong>Keytruda QLEX<\/strong> (subcutaneous): USD 463 million in initial uptake<\/li>\n\n\n\n<li><strong>Formulation Innovation<\/strong>: Subcutaneous injection (pembrolizumab + berahyaluronidase alfa-pmph) offering patient convenience<\/li>\n\n\n\n<li><strong>Market Leadership<\/strong>: Continued dominance in PD-1 inhibitor space despite competitive pressure<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-pipeline-advancement-highlights\" class=\"wp-block-heading\">Pipeline Advancement Highlights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sacituzumab Tirumotecan<\/strong> (sac-TMT): Positive data from TroFuse-005 trial<\/li>\n\n\n\n<li><strong>Indication<\/strong>: Advanced or recurrent endometrial cancer<\/li>\n\n\n\n<li><strong>Technology<\/strong>: TROP2 antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Partnership<\/strong>: Co-developed with Kelun-Biotech<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong>: Expands Merck&#8217;s ADC portfolio beyond existing assets<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-cardiovascular-amp-rare-disease-launches\" class=\"wp-block-heading\">Cardiovascular &amp; Rare Disease Launches<\/h2>\n\n\n\n<h3 id=\"h-winrevair-sotatercept\" class=\"wp-block-heading\">Winrevair (sotatercept)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Q2 Sales<\/strong>: USD 588 million (+75% YoY)<\/li>\n\n\n\n<li><strong>Indication<\/strong>: Pulmonary arterial hypertension (PAH)<\/li>\n\n\n\n<li><strong>Growth Trajectory<\/strong>: Demonstrating blockbuster potential with rapid adoption<\/li>\n\n\n\n<li><strong>Therapeutic Innovation<\/strong>: Novel approach to PAH treatment addressing unmet need<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-lipfendra-enlicitide-approval\" class=\"wp-block-heading\">Lipfendra (enlicitide) Approval<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Milestone<\/strong>: FDA approval received during Q2<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: First and only once-daily oral PCSK9 inhibitor<\/li>\n\n\n\n<li><strong>Indication<\/strong>: LDL-C reduction in adults with hypercholesterolemia<\/li>\n\n\n\n<li><strong>Market Potential<\/strong>: Oral administration offers significant advantage over injectable PCSK9 inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-hiv-pipeline-breakthrough\" class=\"wp-block-heading\">HIV Pipeline Breakthrough<\/h2>\n\n\n\n<h3 id=\"h-once-weekly-oral-hiv-regimen\" class=\"wp-block-heading\">Once-Weekly Oral HIV Regimen<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Combination<\/strong>: Islatravir + lenacapavir<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Positive Phase 3 results announced<\/li>\n\n\n\n<li><strong>Partnership<\/strong>: Collaboration with Gilead Sciences<\/li>\n\n\n\n<li><strong>Therapeutic Innovation<\/strong>: Potential first once-weekly oral HIV treatment regimen<\/li>\n\n\n\n<li><strong>Market Impact<\/strong>: Could revolutionize HIV treatment paradigm with improved adherence<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-business-dynamics\" class=\"wp-block-heading\">Strategic Business Dynamics<\/h2>\n\n\n\n<h3 id=\"h-portfolio-diversification-success\" class=\"wp-block-heading\">Portfolio Diversification Success<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Strength<\/strong>: Keytruda franchise maintaining growth despite patent concerns<\/li>\n\n\n\n<li><strong>Rare Disease Expansion<\/strong>: Winrevair establishing strong foothold in PAH market<\/li>\n\n\n\n<li><strong>Cardiovascular Innovation<\/strong>: Lipfendra approval creates new revenue stream in large cholesterol market<\/li>\n\n\n\n<li><strong>Infectious Disease Leadership<\/strong>: HIV pipeline maintaining Merck&#8217;s historical strength<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-excellence\" class=\"wp-block-heading\">Commercial Excellence<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Launch Execution<\/strong>: Winrevair&#8217;s 75% growth demonstrates effective commercial strategy<\/li>\n\n\n\n<li><strong>Formulation Innovation<\/strong>: Keytruda QLEX subcutaneous option addressing patient preference<\/li>\n\n\n\n<li><strong>Global Reach<\/strong>: Worldwide sales growth reflecting international market penetration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-guidance-amp-strategic-outlook\" class=\"wp-block-heading\">Forward Guidance &amp; Strategic Outlook<\/h2>\n\n\n\n<h3 id=\"h-revised-full-year-expectations\" class=\"wp-block-heading\">Revised Full-Year Expectations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sales Guidance<\/strong>: Raised and narrowed to USD 66.3\u201367.3 billion<\/li>\n\n\n\n<li><strong>Confidence Signal<\/strong>: Reflects strong H1 performance and positive H2 catalysts<\/li>\n\n\n\n<li><strong>Growth Sustainability<\/strong>: Diversified portfolio reducing dependency on any single product<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-pipeline-catalysts\" class=\"wp-block-heading\">Pipeline Catalysts<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lipfendra Commercial Launch<\/strong>: Expected to contribute meaningfully in H2 2026<\/li>\n\n\n\n<li><strong>Sac-TMT Regulatory Pathway<\/strong>: Positive endometrial cancer data supports NDA submission<\/li>\n\n\n\n<li><strong>HIV Regimen Development<\/strong>: Phase 3 success enables regulatory submissions and commercial planning<\/li>\n\n\n\n<li><strong>Keytruda Lifecycle Management<\/strong>: QLEX formulation extending franchise longevity<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-positioning\" class=\"wp-block-heading\">Market Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Focus<\/strong>: Multiple first-in-class and best-in-class assets across therapeutic areas<\/li>\n\n\n\n<li><strong>Partnership Strategy<\/strong>: Strategic collaborations enhancing pipeline depth and commercial reach<\/li>\n\n\n\n<li><strong>Financial Discipline<\/strong>: Strong cash flow supporting both shareholder returns and R&amp;D investment<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, regulatory approvals, and pipeline development. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market access challenges, and clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Q2-2026_Earnings_Infographic_MSD.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Q2-2026_Earnings_Infographic_MSD.\"><\/object><a id=\"wp-block-file--media-6bb17d32-214f-494b-b40f-19b45b75814f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Q2-2026_Earnings_Infographic_MSD.pdf\">Q2-2026_Earnings_Infographic_MSD<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Q2-2026_Earnings_Infographic_MSD.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6bb17d32-214f-494b-b40f-19b45b75814f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71790,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,2675,176,903],"class_list":["post-71787","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of 2026, with total worldwide sales of USD 16.6 billion, growing 4% year-over-year (ex-FX). The company is raising and narrowing its full-year 2026 sales outlook to a range of USD 66.3 billion to USD 67.3 billion, reflecting continued strength in oncology and successful recent launches.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71787\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of 2026, with total worldwide sales of USD 16.6 billion, growing 4% year-over-year (ex-FX). The company is raising and narrowing its full-year 2026 sales outlook to a range of USD 66.3 billion to USD 67.3 billion, reflecting continued strength in oncology and successful recent launches.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71787\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T16:42:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T16:42:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0510.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71787#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71787\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance\",\"datePublished\":\"2026-08-05T16:42:34+00:00\",\"dateModified\":\"2026-08-05T16:42:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71787\"},\"wordCount\":538,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71787#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0510.webp\",\"keywords\":[\"Finanical Reports\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71787#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71787\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71787\",\"name\":\"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71787#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71787#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0510.webp\",\"datePublished\":\"2026-08-05T16:42:34+00:00\",\"dateModified\":\"2026-08-05T16:42:35+00:00\",\"description\":\"Merck & Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of 2026, with total worldwide sales of USD 16.6 billion, growing 4% year-over-year (ex-FX). The company is raising and narrowing its full-year 2026 sales outlook to a range of USD 66.3 billion to USD 67.3 billion, reflecting continued strength in oncology and successful recent launches.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71787#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71787\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71787#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0510.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0510.webp\",\"width\":1080,\"height\":608,\"caption\":\"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71787#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of 2026, with total worldwide sales of USD 16.6 billion, growing 4% year-over-year (ex-FX). The company is raising and narrowing its full-year 2026 sales outlook to a range of USD 66.3 billion to USD 67.3 billion, reflecting continued strength in oncology and successful recent launches.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71787","og_locale":"en_US","og_type":"article","og_title":"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance","og_description":"Merck & Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of 2026, with total worldwide sales of USD 16.6 billion, growing 4% year-over-year (ex-FX). The company is raising and narrowing its full-year 2026 sales outlook to a range of USD 66.3 billion to USD 67.3 billion, reflecting continued strength in oncology and successful recent launches.","og_url":"https:\/\/flcube.com\/?p=71787","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T16:42:34+00:00","article_modified_time":"2026-08-05T16:42:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0510.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71787#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71787"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance","datePublished":"2026-08-05T16:42:34+00:00","dateModified":"2026-08-05T16:42:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71787"},"wordCount":538,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71787#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0510.webp","keywords":["Finanical Reports","Merck Sharp &amp; Dohme","MSD","NYSE: MRK"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71787#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71787","url":"https:\/\/flcube.com\/?p=71787","name":"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71787#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71787#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0510.webp","datePublished":"2026-08-05T16:42:34+00:00","dateModified":"2026-08-05T16:42:35+00:00","description":"Merck & Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of 2026, with total worldwide sales of USD 16.6 billion, growing 4% year-over-year (ex-FX). The company is raising and narrowing its full-year 2026 sales outlook to a range of USD 66.3 billion to USD 67.3 billion, reflecting continued strength in oncology and successful recent launches.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71787#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71787"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71787#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0510.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0510.webp","width":1080,"height":608,"caption":"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71787#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0510.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71787"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71787\/revisions"}],"predecessor-version":[{"id":71791,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71787\/revisions\/71791"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71790"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}